Azitra (AZTR) Q2 2024 earnings summary

Executive summary

• Early-stage clinical biopharmaceutical company focused on precision dermatology using engineered proteins and live biotherapeutic products, with no commercial operations and revenue limited to service agreements, notably with Bayer.

• Pipeline includes ATR-12 (Netherton syndrome, Phase 1b ongoing), ATR-04 (EGFR inhibitor rash, IND planned Q3 2024), and ATR-01 (ichthyosis vulgaris, preclinical), with recent progress in clinical milestones and positive preclinical data presented at major conferences.

• Strategic partnerships with Bayer, Carnegie Mellon, and Fred Hutchinson Cancer Center support R&D and technology development.

• Strengthened intellectual property portfolio with new patents granted and allowed.

• Completed $10 million follow-on offering, extending cash runway into 2025 and supporting upcoming clinical milestones.

Financial highlights

• Total revenue for Q2 2024 was $7,500, down 96% year-over-year; six-month revenue was $7,500, down 97%.

• Net loss for Q2 2024 was $2.63 million, a 41% improvement from Q2 2023; six-month net loss was $5.56 million, a 19% improvement year-over-year.

• Operating expenses for Q2 2024 rose 67% to $2.67 million; R&D expenses increased to $1.1 million and G&A expenses to $1.5 million.

• Cash and cash equivalents at June 30, 2024 were $0.8 million, down from $1.8 million at year-end 2023.

• Completed a follow-on public offering in July 2024, raising gross proceeds of $10 million.

Outlook and guidance

• Initial safety results for ATR-12 Phase 1b trial expected by year-end 2024, with topline data anticipated mid-2025.

• IND for ATR-04 planned for Q3 2024, with Phase 1b trial to commence in Q4 2024 and first patient dosing by year-end.

• Management expects research and development expenses to increase significantly due to planned clinical trial activity.

• Cash on hand after July 2024 offering may not be sufficient for the next twelve months; additional financing will be sought.

• Bayer license agreement update anticipated by year-end 2024.